Impact of oral iron therapy on quality of life in patients with heart failure

Manjunath SM, Janardhan Singh, Kuldeep S. Laller

Abstract


Background: To assess the effect of oral iron supplementation on quality of life (QOL) in anemic patients with heart failure (HF) and to compare QOL with HF patients without iron treatment.

Methods: Sixty anemic patients (Hb 8-11g/dl) with HF (NYHA-class II and III) with LVEF<40% were divided in to 2 groups of 30 each. Group I- received ferrous sulfate 100mg bid x 90 days + standard treatment for HF. Group II- anemic patients received standard treatment for HF only. Primary end point- QOL was measured by MLWHF questionnaire. Secondary end points are Borg scale for dyspnoea and fatigue and exercise tolerance/ capacity in the form of 6 min. walk distance, haematological parameters, efficacy and safety assessment.

Results:  There was significant improvement in QOL in iron treated patients as compared to group II (control). Exercise tolerance /capacity, Borg scale for fatigue and dyspnoea showed improvement in patients received iron for 90 days. Haematological parameters were improved gradually with less incidence of fatigue and pallor. Orally administered ferrous sulfate was well tolerated with mild side effects.

Conclusions: Oral iron supplementation in anemic patients with heart failure improves quality of life/ physical functioning in these patients.


Keywords


Quality of life, Ferrous sulfate, Heart failure, Anemia

Full Text:

PDF

References


Croft JB, Giles WH, Pollard RA,Keenan NL, Casper ML, Anda RF. Heart failure survival among older adults in the United States: A poor prognosis for an emerging epidemic in the Medcare population. Arch Intern Med 1999;159:505-10.

Zannad F, Briancon S, Juilliere Y. Incidence and etiologic features and outcomes of advanced chronic heart failure. The EPICAI study. J Am Coll Cardiol 1999;33:734-41.

Goldberg RJ, Ciampa J, Lessard D, Meyer TE, Spencer FA. Long term survival after heart failure: A contemporary population based perspective. Arch Intern Med 2007;167:490-6.

Lesman-Leegte I, Jaarsma T, Coyne JC, Hillege HL, Van-Veldhulsen DJ, Sanderman R. Quality of life and depressive symptoms in the elderly: a comparison between patients with heart failure and age and gender matched community controls. J Card Fail 2009;15:17-23.

Bullinger M. Health related quality of life and subjective health. Overview of the status of research for new evaluation criteria in medicine. Psychother Psychosom Med Psychol 1997;47:76-91.

Ghali JK, Anand IS, Abraham WT, Fonarow GC, Greenberg B. Krum H. Randomized double blind trial of darbopoietin alfa in patients with symptomatic heart failure and anemia. Circulation 2008;117:526-35.

Rector TS, Kubo SH, Cohn JN. Patients self assessment of their congestive heart failure, part 2 : content ,reliability and validity of a new measure, the Minnesota Living with Heart Failure Questionnaire. Heart Fail 1987;3:198-209.

Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377-81.

ATS Committee on proficiency standards for clinical pulmonary function laboratories. ATS statement: guidelines for the six minutes walk test. Am J Resp Crit Care Med 2002;166:111-7.

Coulter WH. High speed automatic blood cell counter and cell size analyser. Proceeding of national electronic conference 1956;12:1034-40.

Paulus WJ, Van-Ballegoij JJ. Treatment of heart failure with normal ejection fraction: an inconvenient truth. J Am Coll Cardiol 2010;55:526-37.

Kindermann M, Reil JC, Pieske B, Van-Veldhuisen DJ, Bohm M. Heart failure with normal left ventricular ejection fraction: What is the evidence? Trends Cardiovasc Med 2008;18:280-92.

Evangelista LS, Kagawa-Singer M, Dracup K. Gender differences in health perceptions and meaning in person living with heart failure. Heart Lung 2001;30:167-76.

Hurst JW. Exame inicial para diagnostic cardiovascular. Rio de Janeiro: Revinter: 2000; p 29-30.